Sanofi Gains FDA Accelerated Approval for Tzield in Stage 3 Type 1 Diabetes in Pediatric Patients

Sanofi's Tzield (teplizumab-mzwv) has secured FDA accelerated approval for a new indication, delaying endogenous insulin production decline in children aged eight to 17 recently diagnosed with stage 3 type 1 diabetes, a decision that carries a confirmatory study obligation manufacturers in the biologic immunotherapy space should track closely.

The approval rests on a surrogate endpoint: a statistically significant reduction in mean C-peptide decline measured via mixed-meal tolerance test in the PROTECT phase 3 study (NCT03875729), with a least-squares mean difference of 0.13 pmol/mL (95% CI: 0.09–0.17; p<0.001) versus placebo, supported by data from over 900 patients across the broader clinical development program. Under 21 CFR Part 601 Subpart E accelerated approval provisions, continued authorization for this indication remains contingent on verification of clinical benefit through confirmatory trials.

That confirmatory obligation is already active. The BETA-PRESERVE phase 3 study (NCT07088068) is currently enrolling, and its outcomes will determine whether the accelerated approval converts to full approval. For regulatory affairs leads, this enrollment timeline represents a live post-marketing commitment that will require ongoing FDA correspondence and protocol adherence under the confirmatory study framework.

The safety profile observed in PROTECT was consistent with prior Tzield studies. Adverse reactions included lymphopenia, leukopenia, neutropenia, vomiting, rash, diarrhea, elevated liver transaminases, and headache. Serious events, cytokine release syndrome and life-threatening viral reactivation, have been reported, with immunocompromised patients carrying elevated risk. QA and pharmacovigilance teams managing Tzield's post-approval safety reporting will need robust signal-detection protocols aligned with these known risks.

This approval follows an April 2026 FDA label expansion extending Tzield's stage 2 T1D indication to children as young as one year. Tzield now holds approvals across the UK, EU (as Teizeild), China, Australia, Canada, and several additional markets, with regulatory reviews ongoing in other jurisdictions, a multi-region submission landscape that will require coordinated CMC and labeling strategies as each authority processes its dossier.

The BETA-PRESERVE study's enrollment completion and interim readouts will set the pace for Tzield's transition from accelerated to full approval status in this pediatric indication.

Source: GlobeNewswire via Sanofi press release, June 13, 2026.